ArticleFrontiers in dental medicine2026
Effect of polydopamine on bonding characteristics and color stability of blood contaminated Biodentine to composite.
Article in Frontiers in dental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Calcium silicate cements such as Biodentine are frequently placed in a blood-contaminated field during vital pulp therapy and must subsequently be bonded to an overlying resin composite. Polydopamine (PDA) improves the wettability and bond strength of mineral trioxide aggregate to resin composite, but its effect on blood-contaminated Biodentine is unknown. Aim: To determine the effect of PDA pretreatment on the shear bond strength (SBS), failure mode and colour change ( Materials and methods: Seventy-six standardised Biodentine specimens (5 mm diameter × 3 mm) were prepared with blood contamination (present/absent) and PDA pretreatment (present/absent) as the two factors ( Results: Blood contamination significantly reduced SBS [F(1,72) = 18.86, Conclusions: Within the limitations of this
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.